Cocrystal Pharma, Inc. (COCP) Stock Score, Valuation & Financial Research

Cocrystal Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for COCP

Cocrystal Pharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.11. These figures are a research snapshot, not a buy or sell recommendation.

What Cocrystal Pharma, Inc. does

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cocrystal Pharma is a clinical-stage biotechnology company that generates revenue primarily through research and development collaborations and licensing agreements. The company focuses on discovering and developing novel antiviral therapeutics using its proprietary structure-based drug design platform, aiming to monetize its intellectual property through milestone payments and potential future royalties.

Products and services

  • The company is developing a pipeline of small molecule antiviral drug candidates targeting RNA viruses, including influenza, SARS-CoV-2, norovirus, and hepatitis C.

Customer types

Pharmaceutical and biotechnology companies for potential licensing and collaboration.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various third-party contract research organizations to conduct preclinical and clinical studies. Source

Business strengths to evaluate

  • Proprietary structure-based drug design platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party collaborators and clinical trial providers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

COCP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.11
Market capitalization:
15.3M (currency not supplied)
Revenue:
USD 330K
Net income:
USD -9.94M
Free cash flow:
USD -8.2M
Cash:
USD 2.17M
Total debt:
USD 1.34M
EPS:
USD -0.77

What stands out

  • Free cash flow is USD -8.2M, negative for the stored period.
  • The balance sheet shows USD 2.17M of cash versus USD 1.34M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -2486.1% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -3011.5% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 828K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for COCP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can COCP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is COCP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for COCP to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of COCP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research COCP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.